SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SNRS- Sunrise Technologies
SNRS 0.0000010000.0%Jun 6 11:01 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: WILLIAM BLACK who started this subject11/17/2000 6:43:55 AM
From: truthful   of 4140
 
Sunrise Technologies International, Inc. Comments on Market Activity

FREMONT, Calif., Nov. 16 /PRNewswire/ -- Sunrise Technologies International, Inc. (Nasdaq: SNRS - news)

In response to questions from the investment community, Sunrise knows of no reason why the volume in the Company's stock rose today. Sunrise noted there have not been any adverse events to account for the exceedingly high trading volume and decline in the common stock price. The Company is progressing with its business plan of launching its Hyperion LTK(TM) system.

The Company notes that several sites such as AOL and Excite posted press releases from SurgiLight (OTC Bulletin Board: SRGL - news) that erroneously got placed on the Sunrise quote site. Sunrise's trading symbol is ``SNRS''. In fact, one of the headline captions incorrectly labels a SurgiLight press release as a Sunrise press release, which caused confusion among investors. Sunrise is investigating how these errors occurred.

Accurate financial information and press releases about the Company can be obtained by accessing the Sunrise website at www.sunrise-tech.com.

The U.S. Food and Drug Administration approved the Company's HYPERION(TM) LTK System on June 30, 2000 for the temporary reduction of hyperopia in patients with +0.75 TO +2.50 diopters of MRSE with less than or equal to +/- 0.75 diopters of astigmatism, who are 40 years of age or older with documented stability of refraction for the prior 6 months, as demonstrated by a change of less than or equal to 0.50D in spherical and cylindrical components of the manifest refraction. The magnitude of correction with this treatment diminishes over time, with some patients retaining some or all of their refractive correction.

Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties, which may cause actual results to differ materially from the statements made including market potential, regulatory clearances, business growth, and other risks listed from time to time in the Company's Securities and Exchange Commission (SEC) filings. These forward-looking statements represent the Company's judgment, as of the date of this release, and the Company disclaims any intent or obligation to update these forward-looking statements.

Internet users can access Sunrise's World Wide Web site at sunrise-tech.com .

SOURCE: Sunrise Technologies International, Inc.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext